论文部分内容阅读
目的评价联合CIK细胞与化疗方案对比单纯化疗治疗晚期NSCLC的疗效及安全性。方法检索PubMed、EMBASE、Cochrane Library、中国期刊全文数据库等,纳入联合CIK细胞与化疗方案对比单纯化疗治疗中晚期NSCLC的临床研究进行分析。结果共纳入6项研究,349例患者,Meta分析结果显示联合CIK与化疗方案对比单纯化疗方案在有效率(OR=1.90,95%CI:1.20～3.02)、KPS评分(OR=4.26,95%CI:1.90～9.58)方面的差异具有统计学意义,而在1年生存率、2年生存率、粒细胞减少、胃肠道反应、贫血、转氨酶升高方面差异无统计学意义。结论对于中晚期NSCLC患者,联合CIK细胞与传统化疗在提高近期疗效、改善患者生存质量方面及延长生存期方面可能是更好的选择方案,且不会为患者带来比单纯化疗更多的副反应,但需更多高质量随机对照临床研究证实。
Objective To evaluate the efficacy and safety of combination of CIK cells and chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) with chemotherapy alone. Methods PubMed, EMBASE, Cochrane Library, and Chinese Journal Full-text Database were searched for clinical trials of combined chemotherapy of CIK cells and chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Results A total of 6 studies and 349 patients were included in the study. The results of Meta analysis showed that the effective rate (OR = 1.90, 95% CI: 1.20 ~ 3.02), KPS score (OR = 4.26, 95% CI: 1.90-9.58). There was no significant difference in 1-year survival rate, 2-year survival rate, neutropenia, gastrointestinal reaction, anemia and elevated transaminases. Conclusions For patients with advanced NSCLC, combination of CIK cells with conventional chemotherapy may be a better option in improving short-term efficacy, improving patient quality of life and prolonging survival, and will not bring more patients with chemotherapy than chemotherapy alone Response, but more high-quality randomized controlled clinical studies confirmed.